Transplantacija mezenhimalnih matičnih ćelija za ozljedu kičmene moždine: sistematski pregled i mrežna meta-analiza.
Journal of translational medicine
Sažetak istraživanja
Povreda kičmene moždine (SCI) je teška traumatska bolest centralnog nervnog sistema, sa globalnom prevalencom od 236-4187 na milion ljudi. Ova meta-analiza imala je za cilj procjenu sigurnosti i efikasnosti mezenhimalnih matičnih stanica (MSC) u liječenju pacijenata sa SCI, kao i optimalni izvor i metod transplantacije MSC-a. PubMed, OVID, Cochrane, Web of Science i Kineska biomedicinska baza podataka pretražene su do 1. aprila 2021. Studija je provedena za pet krajnjih tačaka: motorički i senzorni rezultat Američkog udruženja za povrede kičme (ASIA), poboljšanje ocjene ASIA, Barthelov indeks (BI) i neželjene reakcije. Standardna meta-analiza i meta-analiza mreže izvedene su pomoću Stata 14.0. Eighteen studies with a total of 949 patients, were included in the meta-analysis. Standardna meta-analiza je pokazala da su MSC značajno poboljšali ASIA motorni skor (P < 0,001), senzorni skor (P < 0,001), ASIA stepen (P < 0,001) i BI (P < 0,001) u poređenju sa rehabilitacijom. Osim toga, u mrežnoj meta-analizi, autologni MSC-ovi su značajno poboljšali ASIA motor [MD = 8,01, 95% CI (4,27, 11,76)], senzorni rezultat [MD = 17,98, 95% CI (10,04, 25,91)] i BI [MD = 8,01, 29,7. 13.29)] u poređenju sa rehabilitacijom. Slično, u poređenju sa rehabilitacijom, intratekalna injekcija (IT) MSC-a značajno je poboljšala ASIA motor [MD = 7,97, 95% CI (4,40, 11,53)] i senzorni rezultat [MD = 19,60, 95% CI (9,74, 29,46)]. Compared to rehabilitation, however, only the IL of MSCs was associated with more adverse reactions [OR = 17.82, 95% CI (2.48, 128.22)]. Prema rezultatima SUCRA-e, i autologni MSC i pristup IT transplantaciji najviše su poboljšali neurološke funkcije kod pacijenata sa SCI. Transplantacija ćelija korišćenjem MSC-a je efikasna kod pacijenata sa SCI i IT autolognih MSC-a može biti korisnija.
Prikaži originalni naslov i sažetak na engleskom
Transplantation of mesenchymal stem cells for spinal cord injury: a systematic review and network meta-analysis.
Spinal cord injury (SCI) is a severe traumatic disease of the central nervous system, with a global prevalence of 236-4187 per million people. This meta-analysis aimed to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) in treating patients with SCI as well as the optimal source and transplantation method of MSCs. PubMed, OVID, Cochrane, Web of Science, and China Biomedical Database were searched up until April 01, 2021. The study was conducted for five endpoints: American Spinal Injury Association (ASIA) motor and sensory score, ASIA grade improvement, Barthel Index (BI), and adverse reactions. Standard meta-analysis and network meta-analysis were performed using Stata 14.0. Eighteen studies with a total of 949 patients, were included in the meta-analysis. Standard meta-analysis showed that MSCs significantly improved ASIA motor score (P < 0.001), sensory score (P < 0.001), ASIA grade (P < 0.001), and BI (P < 0.001) compared to rehabilitation. In addition, in the network meta-analysis, autologous MSCs significantly improved the ASIA motor [MD = 8.01, 95% CI (4.27, 11.76)], sensory score [MD = 17.98, 95% CI (10.04, 25.91)], and BI [MD = 7.69, 95% CI (2.10, 13.29)] compared to rehabilitation. Similarly, compared to rehabilitation, intrathecal injection (IT) of MSCs significantly improved the ASIA motor [MD = 7.97, 95% CI (4.40, 11.53)] and sensory score [MD = 19.60, 95% CI (9.74, 29.46)]. Compared to rehabilitation, however, only the IL of MSCs was associated with more adverse reactions [OR = 17.82, 95% CI (2.48, 128.22)]. According to the results of SUCRA, both autologous MSCs and IT transplantation approaches most improved the neurological function in SCI patients. Cell transplantation using MSCs is effective in patients with SCI and IT of autologous MSCs may be more beneficial.
Izvorni podaci
- DOI
- 10.1186/s12967-021-02843-0
- PMID
- 33910588
- PMCID
- PMC8082850
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom